This update introduced key biomarkers, including1p/19q codeletion for diagnosing oligodendroglioma, and IDH mutation status, along with several other molecular markers and histologic features, to differentiate astrocytoma subtypes. This evidence concerns the gene IDH2 and oligodendroglioma.